Cancer BiologybioRxivPreprint
NNV024, a novel humanized anti-CD37 antibody with enhanced ADCC and prolonged plasma half-life in human FcRn transgenic mice for treatment of NHL
R. Generaloc, E. Fiorito, S. Foss…·J. Dahle
This paper develops NNV024, a humanized anti-CD37 antibody with enhanced ADCC and prolonged plasma half-life, showing improved efficacy against NHL and CLL cells compared to existing therapies.